>

H Lundbeck Financials

<div class='circular--portrait' style='background:#0D8ECF;color: white;font-size:6em;padding-top: 0px;;'>H</div>
Understanding current and past H Lundbeck Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. We strongly advise to harness H Lundbeck fundamental analysis to find out if markets are at this moment mispricing the company. Simply put this interface allows you to validate available fundamentals of H Lundbeck AS as well as the relationship between them. We found thirty-three available reported financial drivers for H Lundbeck AS, which can be compared to its competitors. To make sure the equity is not overpriced, please check out all H Lundbeck financials, including its Price to Sales, Gross Profit and the relationship between Price to Book and Revenue .
View Fundamentals For
Refresh
With this module, you can determine H Lundbeck financials for your investing period. You should be able to track the changes in H Lundbeck individual fundamental values over time to develop the understanding of its risk, liquidity, profitability, or other critical and vital indicators.
1%1%

Chance of Financial Distress

H Lundbeck AS has less than 1 (%) percent chance of experiencing financial distress in the next 2 years of operations. More Info

H Lundbeck Company Summary

H Lundbeck competes with Zealand Pharma. Lundbeck AS engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, North America, and internationally. The company was founded in 1915 and is headquartered in Valby, Denmark. H Lundbeck operates under Drug Manufacturers - Specialty Generic classification in Denmark and is traded on Copenhagen Stock Exchange. It employs 5143 people.
Specialization
Healthcare, Pharmaceuticals And Biosciences
InstrumentDenmark Stock View All
ExchangeCopenhagen Stock Exchange
ISINDK0010287234
Business AddressOttiliavej 9
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
BenchmarkDOW
Websitewww.lundbeck.com
Phone45 36 30 13 11
CurrencyDKK - Danish Krone

H Lundbeck Key Financial Ratios

H Lundbeck Financial Ratios Relationships

H Lundbeck AS is considered the number one company in revenue category among related companies. It is currently regarded as number one stock in cash and equivalents category among related companies creating about  0.28  of Cash and Equivalents per Revenue. The ratio of Revenue to Cash and Equivalents for H Lundbeck AS is roughly  3.55 

H Lundbeck Market Fundamentals

Follow Benchmarks with Macroaxis syndicated feed, custom widget, or your favorite custom stock ticker
Check out Stocks Correlation. Please also try Volatility Analysis module to get historical volatility and risk analysis based on latest market data.
Company logos by clearbit
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page